Minireviews
Copyright ©The Author(s) 2021.
World J Hepatol. Nov 27, 2021; 13(11): 1663-1676
Published online Nov 27, 2021. doi: 10.4254/wjh.v13.i11.1663
Table 2 Direct-acting antiviral agents and liver cirrhosis related events
Ref.
Study design
Number of patients
Drugs
HCC
Portal hypertension-related complications
Kozbial et al[32], 2018Prospective551DAA16 (4.1%)Ascites: 3.1%; variceal hemorrhage: 1%; hepatic encephalopathy: 0%
Masuzaki et al[36], 2009Prospective984DAA77 (2.9% per 1 person-year); HCC risk: 45.5 times higher in LS > 25 kPaNA
Afdhal et al[39], 2017Prospective50DAALS improvement in patients who did not develop HCC during follow-up (42.6% reduction in patients without HCC vs 13.6% in HCC group)24% patients had ≥ 20% decreases in HVPG during treatment (89% subjects with baseline HVPG ≥ 12 mmHg had a ≥ 20% reduction in HVPG after SVR)
Giannini et al[51], 2019Prospective52DAA4 (7.7%)Clinical decompensation: 0%
Tachi et al[58], 2017Prospective263DAA19 (7.2%)NA
Foster et al[60], 2016Retrospective, observational467DAANAMELD improvement (0.85, SD 2.54); composite adverse outcome in 52.0% (treated) vs 61.7% (untreated)
Rinaldi et al[63], 2019Multicenter, prospective258DAA35 (13.6%)NA
Ravaioli et al[68], 2018Retrospective139DAA20 (14.4%)NA
Pan et al[70], 2018Retrospective84DAA4 (4.8%)NA
Toyoda et al[75], 2015Retrospective/prospective522IFN-based18 (1.2% after five yr; 4.3% after ten yr)NA
D’Ambrosio et al[77], 2018Prospective38DAA5 (13%)Clinical decompensation: 0%
Lleo et al[78], 2019Prospective1927DAAPrevious HCC: 38/161 (recurrence rate: 24.8 per 100-yr); No previous HCC: 50/1766 (incidence rate: 2.4 per 100-yr)NA
Hamada et al[79], 2018Retrospective196DAA8 (4.1%)NA